NASDAQ
Eiger BioPharmaceuticals, Inc. (EIGRQ) has a free cash flow growth of 4.12% as of Friday, May 29, 2026. This represents a 37.73% decrease compared to its 12-month average of 6.61%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.